Stockwatch: An oasis of lipid-lowering therapies and a desert of reimbursement
This article was originally published in Scrip
Executive Summary
Last week was chock-full of commentary from the FDA Advisory Panels on the new lipid-lowering drugs directed against PCSK9 from Amgen and Sanofi/Regeneron Pharmaceuticals. Amongst those and other related companies, the only share price winner of the week was Sanofi, with its main listing outside of the US, and even then it was for the wrong reason.